A recent study discovered that the expression levels of FABP4 and MMP9 can effectively identify patients who are at risk of progressing from MAFLD to MASH, as well as those at risk of advancing from MASH to cirrhosis and HCC, respectively [34]. Here, FABP4 is linked to metabolic dysfunction-associated steatohepatitis.